Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience John Crown, Michael O'Leary, Wei-Seong Ooi Oncologist 2004; 9(Suppl 2): 24-32 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe randomized trial data from studies evaluating taxanes in anthracycline-naïve or anthracycline-pretreated metastatic breast cancer patients. Discuss recent findings of randomized trials evaluating docetaxel as neoadjuvant therapy. Compare and contrast efficacy end point data from three adjuvant taxane trials with mature results. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 25, 2004 Most Recent Review: May 25, 2004* Most Recent Update: May 25, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes.